Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
about
Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustatRandomized, controlled trial of miglustat in Gaucher's disease type 3.Gaucher disease and the clinical experience with substrate reduction therapy.Gastrointestinal disturbances and their management in miglustat-treated patients.A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?Gaucher disease: clinical profile and therapeutic developments.Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1.Biochemistry of glycosphingolipid storage disorders: implications for therapeutic interventionSwitching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority studyBiochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patientsPharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders.Review of miglustat for clinical management in Gaucher disease type 1.Substrate reduction therapy.Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustatReal-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.Synthesis and evaluation of eight- and four-membered iminosugar analogues as inhibitors of testicular ceramide-specific glucosyltransferase, testicular β-glucosidase 2, and other glycosidases.Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction.Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.Miglustat in Niemann-Pick disease type C patients: a review
P2860
Q26825102-DA992CA2-A333-4EF8-AAA0-EE4218F56B98Q30485096-33F6868A-21C8-4CEB-A6FF-E5134845DA69Q33348495-130BCF52-33A2-48A0-BBF8-88C095C9F4A7Q33451316-F4FABFF6-22F8-4E45-852B-E032BE013395Q33465330-B28FA61B-DC04-4EFD-8C44-69474DC92178Q33717397-BCE7C711-E2C2-4611-90BF-4746BB8286EAQ34443517-538CE7C8-DB4C-4DFC-AD18-49C88EEA6233Q34557737-365ADA11-C5D3-48DF-98E2-E5E14A9B07C1Q34582069-5CAF66E4-E624-4F59-9EEA-41A649DE2B14Q35028532-6DF01AE6-9595-441C-92DB-5F1AA880A7FBQ35056076-D455032F-348A-45E7-B5E1-3CA24D77C091Q35153233-FCABDEB7-D6BC-490D-B528-A5419132FDF0Q35806919-E7CDD80E-DB6C-445E-89F3-39321F97DB50Q36556379-C6994727-9E24-44EE-B7D2-A89B575C10AFQ36725221-3520E4EA-9DF8-4F67-A42C-18CDD26CB579Q36739788-CDC9B661-BE79-429F-868E-7B64023CD0C1Q36823551-77F1EEB6-38E7-461E-9B23-7FE0C9AF5A8DQ37109614-AFC1A7C8-0F57-4922-93F0-0ED55B24BAFAQ37400927-2BA35429-D941-43C8-A253-F5745E9433A7Q37429819-3ED7DA98-B9CC-4792-B993-76DDB3CD4E91Q37470861-8120B3DC-32C6-4ED7-BDA5-606E64783E0CQ41471477-A2B54DE1-BFDC-46D5-8DA0-4F12168975BDQ42322397-358088E9-E88E-4D78-A159-70A4C710D700Q45267679-6F236B99-517C-427C-8BF6-F6FC6CC4A70CQ47548732-E1264E9A-656B-45D5-B877-265CF6FA6596Q58778074-C65E5D9F-7C31-4241-832D-3C88574817A3
P2860
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
@en
Low-dose N-butyldeoxynojirimycin
@nl
type
label
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
@en
Low-dose N-butyldeoxynojirimycin
@nl
prefLabel
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
@en
Low-dose N-butyldeoxynojirimycin
@nl
P2093
P356
P1476
Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease
@en
P2093
Ari Zimran
Deborah Elstein
Rene Heitner
Sonja van Weely
P304
P356
10.1006/BCMD.2002.0497
P50
P577
2002-03-01T00:00:00Z